HUMANA INC Earnings Summary — Q1 2026

• Revenue grew by 23.47% year-over-year to $39.65 billion, driven by strength in Medicare Advantage premiums.
• Net income of $1.18 billion reflects a 4.67% decline compared to Q1 2025, signaling persistent cost pressures.
• Insurance benefits and claims surged to $33.7 billion, up nearly 27% from $26.5 billion in the prior year period.
• Operating income recovered significantly from the Q4 2025 loss, though it remains below Q1 2025 peak levels of $2.01 billion.
• The 10x top-line expansion seen over the last decade has decoupled from profitability as medical loss ratios rise.
• Strategic focus has shifted toward cost-containment and risk-mitigation to protect margins against regulatory headwinds.
• Total non-operating expenses improved to $159 million, down from $323 million in the same quarter last year.

Management focus has pivoted from growth-oriented optimism to strict cost-containment and risk-mitigation strategies due to adverse regulatory shifts.

Stable

While revenue growth remains excellent, the inability to translate this into bottom-line expansion due to rising benefit costs keeps the outlook cautious.

Humana faces a challenging environment characterized by rising Medical Loss Ratios (MLR) and regulatory pressure on Medicare Advantage reimbursement. Future earnings depend heavily on the accuracy of forecasting medical benefit ratios and navigating CMS reimbursement changes.